engineered regulatory T cell therapy (GentiBio)

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug Nameengineered regulatory T cell therapy (GentiBio)
Drug Alias NameGNTI-122
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunosuppressantsRegulatory T-lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGentiBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesGentiBio Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A